"We know for sure that the vaccine can be used by all people aged over 18, we will now go down [proceed to vaccination of younger citizens]. We understand that vaccine injection results in the development of effective antibodies in 94 percent of cases," Alexander Semyonov told the Soloviev Live YouTube show.
31 March 2021, 01:08 GMT
Russian consumer rights watchdog Rospotrebnadzor specified later that Semyonov was talking about antibodies in people aged 60+.
EpiVacCorona vaccine was authorised for seniors aged 60 and over in March.
The vaccine is a peptide-based drug that relies on a synthetic platform. Artificially-synthesised short fragments of viral proteins - peptides, which are contained in the vaccine, help the immune system learn how to recognise and then neutralise the virus.
